A panel of advisers overruled the FDA's own scientists in July. Fourteen banned peptides are heading back toward legal. You will see this reported as peptides being approved. It is not that, and in Europe it changes nothing at all.
What changed, and where
A rule moved in
the United States.
Nothing moved in Europe.
AJMC and Sheppard Mullin, July 2026
On the second day, when the first vote was read out, people in the room gasped.
The meeting was at the FDA's campus in Silver Spring, Maryland, on 23 and 24 July. A panel of advisers had been asked a narrow question about four peptides: BPC-157, TB-500, KPV and MOTS-c. Should US pharmacies be allowed to make them up for patients?
The FDA's own scientists had already answered in writing. No, to all four. Their reason was simple. There was almost no human safety data. For BPC-157, the most popular of them, the only human evidence they could find was a decades-old conference note that was never published.
The panel voted the other way. Six out of seven, in favour. The American Journal of Managed Care notes that an FDA panel had rarely, if ever, voted against its own staff's written advice. Hence the gasp.
That vote is now being sold as peptides going legal. It is worth being clear about what happened.
The FDA put 19 peptides on a restricted list, meaning US pharmacies could no longer make them up for patients.
Separately, the FDA took tirzepatide off its drug shortage list. Pharmacies had only been allowed to make it because of that shortage. When it came off, that stopped.
The FDA moved to restrict ingredients used in mass-produced copies of semaglutide and tirzepatide, and to stop sellers calling those copies "generic" or "equivalent".
The health secretary announced that about 14 of the 19 would move back toward being allowed again.
The panel met, the FDA's scientists said no to all four, and the panel recommended six of seven anyway.
Twelve peptides have come off the restricted list. Only one, GHK-Cu, has actually moved to the allowed list. The panel's vote is advice, not a decision. The rules that would follow it usually take one to two years to write. Another meeting on five more peptides is due before the end of February 2027.
AJMC / eight new panel members
This will get twisted, so here it is flat.
Moving a peptide to the allowed list means a US pharmacy can make it up for a named patient who has a prescription. That is all it means.
It does not mean the FDA approved it. There is no approved use. There is no official dose. There is no finding that it is safe or that it works.
The FDA's own scientists looked at BPC-157, TB-500, KPV and MOTS-c. They said no to all four. The reason was that there was almost no human safety data. That advice was not withdrawn. It was outvoted.
AJMC reports the panel now has eight new members who back looser rules. Most of them have money ties to businesses that sell or hand out peptides.
Every seller in this market has an interest in the first half of that story and none in the second. Both halves are true at the same time. A seller who leaves the second one out has told you something about how they handle awkward facts, and that is worth more to you than the fact itself.
The FDA is an American agency. Its rules cover American pharmacies. They do not apply in Germany, France, Italy, the Netherlands, Croatia or anywhere else in the EU.
So if you are in Europe, take exactly one legal conclusion from the July vote: none. Your own country's medicines law sets the legal position where you live. None of that moved in July. If it matters to you, ask a lawyer in your country. Not a supplier, and not a forum.
Some sellers in Europe will use the FDA news to suggest these compounds are now legal, approved, or safer where you live. Anyone doing that is either confused or hoping you are. It is a rule change about American pharmacies. That is the whole of it.
Underneath the politics, the real argument at the FDA was never whether these molecules are interesting. It was whether anyone can tell what is actually in a vial. That question does not care which country the vial is in.
AJMC summarised what independent lab testing of grey market product has turned up. Three separate problems:
| What testing found | Why a purity number misses it |
|---|---|
| Bacteria | Bad enough in reported cases to cause blood infections. Purity measures the molecule, not what is sitting around it. |
| Heavy metals and leftover solvents | Left over from making it. Also invisible to a purity figure. |
| Short vials | Some products held far less than the label said. A vial can be 99 percent pure and still short. |
None of that has anything to do with American law. Those are facts about how a batch was made, and they travel with the batch.
“What we need to standardize is that patients need to know what's in the vial, whether it's made consistently, and whether the compounding pharmacy making it is following the right protocols.”
Rachel Strauss, PBM Princess, quoted in AJMC
That is the whole question. You can answer it today, without waiting two years for rule writing in another hemisphere. You answer it with a lab report. From a lab that did not sell you the vial, tied to the batch number on the vial you got.
None of it changes what a buyer can actually check. A published certificate from an
outside laboratory, tied to a batch number printed before you order, does the same work in
Europe today that it did before any of this. Crystal Peptides publishes one for Retatrutide
20mg: Janoshik, batch RT6423CP, purity 99.744 percent, 22.43 mg against a 20mg
label, analysed 25 May 2026, with a key you check at the laboratory.
On the contamination findings above, honesty needs a second sentence. Identity, purity and amount are one set of tests. Endotoxin, heavy metals and sterility are a separate panel with a separate report. Ask any seller which of the three they run, and whether the result sits on the certificate for your lot.
One: which outside lab tested the batch I would get, and can I see that batch's report? Two: which contamination tests do you run, if any? A supplier who points at the FDA news but cannot answer either has answered a question you did not ask.
Every seller looks the same on the good day. Four things decide what happens on the bad one, and all four are published before you order if you go and read them.
Read the seller's own published pages, not their marketing, and none of these terms were written by us.
One page on what the FDA actually changed, what it did not, and what none of it means in Europe.
You are on the list.
The sheet comes by email, as one page you can print.
It follows once our list is live, and nothing else is sent. We do not sell peptides and we are not going to email you about any.
One email with the sheet. Unsubscribe in one click. We do not share addresses.
Before you go
One sheet, in plain language, that you can run on any seller in any country. One column filled in from a published certificate, and one left empty for the seller you already have open.
You are on the list.
The sheet comes by email, as one page you can print.
Nothing else follows it. We do not sell peptides and we are not going to email you about any.
One email with the sheet. Unsubscribe in one click. We do not share addresses.